Beyond HNSCC, this work may lay a foundation to study IL-1 ligands as biomarkers for responsiveness to cetuximab in colorectal cancer and in immune activating agents in other disease sites as well. The gene discussed is IL1A; the disease is head and neck squamous cell carcinoma.